Drug Name Review Pilot Tailors Requirements For OTC Participants
This article was originally published in The Tan Sheet
Executive Summary
OTC drug manufacturers participating in FDA's trade name pilot will be required to include consumers in their simulation safety studies and review entire labels, not only product names